Biontech’s new corona vaccine is coming in October

Biontech's new corona vaccine is coming in October

Biontech and its partner Pfizer have started manufacturing so-called bivalent corona vaccines adapted to the omicron variants BA.1 and BA.4/5. This was announced by the Mainz-based biotech company on Monday when it presented its quarterly figures. Subject to official approvals, one plans that vaccine to be delivered from October and to be made available in time to support the booster campaigns in the autumn.

Biontech’s American competitor is pursuing similar plans Moderna , which also produces mRNA vaccines against the coronavirus. The goal is to bring two combined Covid 19 booster vaccines onto the market in the fall, if they are approved, it said in mid-July. This is a reaction to different market preferences for omicron sub-variants.

Biontech and Moderna had developed and pre-produced a vaccine adapted to the BA.1 variant that was circulating at the time. In the meantime, however, the BA.4/BA.5 omicron strain has become dominant, which is why suppliers there are concentrating on this variant according to the latest recommendations from the US Food and Drug Administration (FDA). For Germany, Federal Health Minister Karl Lauterbach (SPD) is also pushing for the appropriately adapted vaccine.

“Our Covid-19 product pipeline includes variant-adapted vaccine candidates as well as next-generation vaccine candidates aimed at longer and broader protection,” said Biontech boss Ugur Sahin. CFO Jens Holstein explained that demand is expected to increase in key markets in the fourth quarter. The company confirmed its forecast for the 2022 financial year. According to this, sales of Covid-19 vaccines are planned to be in the range of 13 to 17 billion euros. In 2021 it was almost 19 billion euros. Net profit last year was almost 10.3 billion euros.

Source link